Skip to Content

StageZero Life Sciences Ltd SZLSF

Morningstar Rating
$0.01 0.00 (8.05%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

SZLSF is trading at a 538% premium.
Price
$0.01
Fair Value
$4.73
Uncertainty
Extreme
1-Star Price
$6.31
5-Star Price
$4.86
Economic Moat
Wfkl
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SZLSF is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$0.01
Day Range
$0.000.01
52-Week Range
$0.000.06
Bid/Ask
$0.00 / $0.04
Market Cap
$1.48 Mil
Volume/Avg
8,717 / 70,857

Key Statistics

Price/Earnings (Normalized)
0.01
Price/Sales
0.46
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

StageZero Life Sciences Ltd is a vertically integrated healthcare company at the nexus of three sectors of healthcare; Early Cancer Detection, Liquid Biopsy, and Global Telehealth. It is focused on minimizing the risk of cancer and other chronic diseases through early detection and intervention. It continues to develop and commercialize proprietary molecular diagnostic tests for the early detection of diseases and personalized health management, with a focus on cancer-related indications. It has developed a proprietary platform technology, the Sentinel Principle, to identify novel biomarkers from whole blood. The Company's lead product, Aristotle, is a blood-based molecular diagnostic assessment that can detect an individual's current risk for potentially having a variety of cancers.
Sector
Healthcare
Industry
Diagnostics & Research
Stock Style Box
Small Value
Total Number of Employees
40

Valuation

Metric
SZLSF
Price/Earnings (Normalized)
0.01
Price/Book Value
Price/Sales
0.46
Price/Cash Flow
Price/Earnings
SZLSF

Financial Strength

Metric
SZLSF
Quick Ratio
0.01
Current Ratio
0.02
Interest Coverage
−37.52
Quick Ratio
SZLSF

Profitability

Metric
SZLSF
Return on Assets (Normalized)
−199.34%
Return on Equity (Normalized)
Return on Invested Capital (Normalized)
Return on Assets
SZLSF
See how this stock stacks up to its competitors with Morningstar Investor

Diagnostics & Research Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Thermo Fisher Scientific Inc
TMO
SbyxyphfsZrky$215.5 Bil
Danaher Corp
DHR
XscfyqcmZkmgn$188.8 Bil
IDEXX Laboratories Inc
IDXX
VtlpggddJxvxck$40.9 Bil
IQVIA Holdings Inc
IQV
YlrntjxbMjdwtv$39.4 Bil
Agilent Technologies Inc
A
McrfjkjrmSdlyw$38.9 Bil
Mettler-Toledo International Inc
MTD
JtqjblgjdYfdcvd$31.3 Bil
Icon PLC
ICLR
JrhryjbwYwzyt$26.4 Bil
Labcorp Holdings Inc
LH
ZysxyfzyvYvssd$17.3 Bil
Illumina Inc
ILMN
DnswcmhvdTygxbpq$17.3 Bil
Waters Corp
WAT
TnmpbcwnmLht$17.2 Bil

Sponsor Center